NEW YORK – Azalea Therapeutics launched on Tuesday, having raised $82 million in seed and Series A financing to develop in vivo genetic medicines for cancer and autoimmune conditions using its ...

In a bid to help children suffering from a rare and life-threatening genetic disorder, Member of Parliament from Delhi’s Chandni Chowk, Praveen Khandelwal, has written to Prime Minister Narendra Modi, ...

The grantmaking organization Open Philanthropy has awarded funding for a University of California San Diego technology ...

The Point-of-Care Molecular Diagnostics Market is experiencing robust expansion driven by rising demand for rapid, accurate, ...

Recognized in the Biotechnology category of the 2025 Top Innovations contest, small Cas12l nucleases are versatile, ...

CRISPR technology could one day create “designer babies, ” raising major ethical and social inequality concerns.

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

It is a smart strategy to diversify your portfolio by investing in high-quality companies built on proven technologies.

According to Nova One Advisor, the global gene editing market size is calculated at USD 11.29 billion in 2025 and is expected ...

Agreement with IRRI marks Pairwise's third CGIAR partnership, enabling the research institute to use Fulcrum® genome editing technology to develop higher-yielding, more nutritious rice varieties that ...